Fresenius Group, consisting of Fresenius Medical Care, Fresenius Kabi, Fresenius Hellos and Fresenius Vamed, has achieved significant growth in sales and earnings during the quarter ended June 2010. The Group's net income increased by 41 per cent to Euro 183 million from Euro 130 million in the corresponding period of last year. Its sales moved up by 14.8 per cent to Euro 4,043 million from Euro 3,522 million. The earnings per share for the quarter improved to Euro 1.12 from Euro 0.81 in the last period.

For the first half ended June 2010, Fresenius' net income increased by 25.8 per cent to Euro 302 million from Euro 240 million in the similar period of last year. Its sales went up by 11.5 per cent to Euro 7,686 million from Euro 6,895 million.

Ulf Mark Schneider, CEO Fresenious SE, said, "Our continued focus on revenue growth and the Group's operating margin proved to be successful. All business segments achieved excellent financial results. Fresenius Kabi significantly exceeded our expectations, primarily due to the successful sales and earnings development of APP Pharmaceuticals in North America. We are very confident about our prospects for the second half of 2010 and raise our earnings outlook for the Group."

The group expects net income to increase by 10 per cent to 15 per cent in constant currency in 2010. Previously, the company expected net income to increase by 8 per cent to 10 per cent inconstant currency. The group plans to invest approximately 5 per cent of sales in property, plant and equipment.

In Europe, sales grew by 9 per cent and that in North America by 11 per cent. Group's EBITDA increased by 13 per cent to Euro 1,425 million in first half as against Euro 1,260 million in the same period of last year. The Group spent Euro 320 million on property, plant and equipment as against Euro 283 million in the last period. Acquisition spending was Euro 151 million as compared to Euro 156 million. The Group's total assets grew by 14 per cent to Euro 23,907 million from Euro 20,882 million.

The Group company, Fresenius Medical care reported sales of Euro 4,392 crore during the first half of 2010 as against Euro 3,994 million, a growth of 10 per cent. Fresenius Kabi achieved sales growth of 16 per cent to Euro 1,745 million from Euro 1,500 million and Fresenius Hellos clocked sales of Euro 1,223 million as against Euro 1,164 million. Fresenius Vamed, a relatively small company in Group, posted sales of Euro 338 million as compared to Euro 247 million in the same period of last year. The net earnings of all group companies improved between 10 per cent to 60 per cent during the first half of 2010.